Studies of Left Ventricular Dysfunction (SOLVD)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000516
First received: October 27, 1999
Last updated: April 26, 2012
Last verified: April 2012
  Purpose

To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.


Condition Intervention Phase
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Heart Failure
Hypertension
Myocardial Ischemia
Drug: enalapril
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: July 1985
Study Completion Date: May 1990
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000516

Sponsors and Collaborators
Investigators
Investigator: Clarence Davis University of North Carolina
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00000516     History of Changes
Other Study ID Numbers: 35
Study First Received: October 27, 1999
Last Updated: April 26, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Coronary Disease
Heart Diseases
Heart Failure
Hypertension
Ischemia
Ventricular Dysfunction, Left
Ventricular Dysfunction
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Pathologic Processes
Enalapril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 24, 2013